APCDD1 and cancer: The [D-Gln4]LR peptide and its lead, LR, have exhibited cancer cell-growth inhibitory activity by mainly reducing the abundance of the active form of hTS, and, unlike 5-FU and PMX, without inducing overexpression of the enzyme [19,21], but even by down-modulating the expression of other folate pathway genes, DHFR and AICAR transformylase (ATIC) [22].